AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

This year the biosimilars to Stelara (ustekinumab) stand to be the stars of the biosimilars show. The FDA has approved seven ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

The global online pharmacy market size was valued at USD 112.46 billion in 2024 and is projected to reach from USD 131.65 billion in 2025 to USD 543.36 billion by 2033, growing at a CAGR of 17.06% ...

AbbVie stock trades at a forward price-to-earnings (P/E) ratio of 14.2, representing a significant discount to the S&P 500's ...

Tom Lee, Fundstrat Global Advisors managing partner and head of research, appeared on CNBC to talk about his 2025 playbook.